All the news Showing 10 of 56 articles from: Treatment outcomesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Generic DAAs achieve excellent cure rates in Egypt matching those of branded drugs at a fraction of the cost Michael Carter / 01 February 2019 Generic direct-acting antivirals (DAAs) are just as effective and safe as their branded equivalents for the treatment of chronic hepatitis C virus (HCV) infection, according to Egyptian research published in Liver International. Generics achieved ... Sofosbuvir/ledipasvir cures most young children with hepatitis C Liz Highleyman / 13 November 2018 Almost all young children ages 3 to 6 years with chronic hepatitis C achieved sustained virological response after 12 weeks of treatment using sofosbuvir/ledipasvir oral granules, according to findings presented at the ... Successful hepatitis C treatment lowers risk of cardiovascular events Liz Highleyman / 25 October 2018 Treatment for hepatitis C, especially if it leads to a cure, is associated with a reduced risk of cardiovascular events such as congestive heart failure, heart attacks and strokes, according to research presented ... Psychological relief is the most important benefit of a hepatitis C cure for patients Roger Pebody / 13 September 2018 When asked to describe what their hepatitis C cure meant to them, Australians who had recently completed treatment emphasised an improved sense of psychological wellbeing, according to a qualitative study recently published in ... Reinfection risk after hepatitis C treatment higher in recent drug users Keith Alcorn / 07 September 2018 Reinfection with hepatitis C after successful treatment is more common in younger people who inject drugs and recent and former drug users are at greatest risk of reinfection, a cohort study in ... Advent of DAAs accompanied by dramatic improvement in survival after HCV-related liver transplant Michael Carter / 18 July 2018 Survival among people with hepatitis C virus (HCV) undergoing liver transplant has improved significantly since the introduction of direct-acting antivirals (DAAs), investigators from Catalonia report in the Journal of Hepatology. Thanks to DAAs, there ... Over 300,000 people waiting for hepatitis C treatment in the United States Keith Alcorn / 20 June 2018 At least 300,000 people were awaiting treatment for hepatitis C by the end of 2016 in the United States, with the lowest rates of treatment observed in the Upper Midwest, ... Fatty liver improves rapidly after hepatitis C cure Michael Carter / 18 June 2018 Liver stiffness and liver fat (steatosis) in people with chronic hepatitis C virus (HCV) infection both improve significantly after treatment with direct-acting antivirals (DAAs) resulting in sustained virological response (SVR), ... Does portal hypertension always improve after hepatitis C cure? Keith Alcorn / 10 May 2018 Although portal hypertension improves in the majority of people with hepatitis C and cirrhosis after hepatitis C is cured, not all people experience improvement, and oesophageal varices may continue to ... Fewer non-liver cancers in people treated with DAAs compared to the interferon era Keith Alcorn / 02 May 2018 The risk of non-liver cancer is lower in people treated with direct-acting antivirals (DAAs) than in those treated with interferon and is probably an effect of the improved cure rate ... ← Prev12345...6Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive